GT
Gaba Therapeutics is developing GRX-917, a deuterated analog of an established anxiety medication that offers comparable efficacy to benzodiazepines without the risk of addiction or significant side effects. This compound enhances endogenous neurosteroid production to modulate GABAa receptors, targeting generalized anxiety disorder and potentially benefiting various neuropsychiatric and neurological conditions.
Updated 4 months ago
Funding
$22M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Gaba Therapeutics is developing GRX-917, a deuterated analog of an established anxiety medication that offers comparable efficacy to benzodiazepines without the risk of addiction or significant side effects. This compound enhances endogenous neurosteroid production to modulate GABAa receptors, targeting generalized anxiety disorder and potentially benefiting various neuropsychiatric and neurological conditions.